title: Novel therapies for multiple myeloma.
authors.affiliation: Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Hayashi
authors.forename: Teru
authors.initials: T
authors.lastname: Hideshima
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
mesh_terms: D000077584:2-Methoxyestradiol; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000473:pathology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006575:Heterocyclic Compounds, 3-Ring / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D010087:Oxides / Q000627:therapeutic use; D010793:Phthalazines / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001152:Arsenicals; D004791:Enzyme Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D016328:NF-kappa B; D010087:Oxides; C456319:PS1145; D010793:Phthalazines; D011480:Protease Inhibitors; D011725:Pyridines; D004958:Estradiol; D013792:Thalidomide; C404768:vatalanib; D000077584:2-Methoxyestradiol; D011505:Protein-Tyrosine Kinases; D000077237:Arsenic Trioxide